

To: (10)(2e)@minvws.nl[(10)(2e)@minvws.nl]
From: (10)(2e)@gllcmedical.com
Sent: Thur 5/21/2020 8:13:31 AM
Subject: Covid-19 test-strategy - potential collaboration?
Received: Thur 5/21/2020 8:14:17 AM

Dear (10)(2e)

I hope my e-mail finds you well. I'm trying to locate the responsible team for your Covid-19 test-strategy planning, and would greatly appreciate if you can guide me in the right direction?

We have recently released a very high quality, Rapid Diagnostic Test-kit for IgG and IgM antibodies against SARS-CoV-2 (Colloidal Gold-based) to be used by front-line healthcare professionals (nurses, doctors, etc.) and are currently looking for collaboration-partners.

To date we have conducted more than 3,000 random tests combined with 300 controlled tests – both indicating an accuracy rate better than 99%. By early June we're expecting the first comprehensive, independent clinical study performed by (10)(2a) in (10)(2a) with the initial data-release indicating >94% sensitivity and >98% specificity - numbers we're obviously proud of.

On top, our RDT is now live in (10)(2a) (10)(2a) (10)(2a) and (10)(2a) and in parallel, we are providing samples to a number of National Medicine Agencies and their microbiology/virology labs - in Europe, Asia and Africa, for additional independent performance validation.

If there may be an interest in potentially adding a high quality and easy-to-use supplemental tool to your regional or national testing-arsenal in the long-term fight against SARS-CoV-2, I'd be happy to establish a collaboration between us and send you a number of samples (i.e. (10)(2a) for your own testing, validation and comparison with existing or planned testing-methods.

In hoping for your positive considerations, I'm looking forward to hearing from you.

With best regards

(10)(2e)

--

(10)(2e) (10)(2e) (PA)

GLLC-Medical Ltd.

Hagenholzstrasse 83B

CH-8050 Zürich

E-mail: (10)(2e)@gllcmedical.com

Tel: (10)(2e)

Web: <https://gllcmedical.com>